Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs and new biomarkers as they become available.
The first trial of its kind in solid tumours, FOCUS4 will divide around 2,400 patients into different, smaller groups depending on specific biomarkers found in their tumour. These biomarkers will then be used to predict the targeted treatments that patients are most likely to benefit from.
The trial is jointly funded by the Medical Research Council (MRC) and National Institute for Health Research (NIHR) through the Efficacy & Mechanism Evaluation (EME) programme and Cancer Research UK, through its partnership with Stand up to Cancer and Channel 4.
Patients with advanced bowel cancer will first receive the standard four months of chemotherapy and have their cancer biopsy analysed for a number of biomarkers at the same time. Based on the test results, patients will be offered enrolment into a sub trial that will test a new drug targeted at their specific type of bowel cancer.
And for those who don't have any of these biomarkers, or if there are no open sub trials for their biomarkers, they will be offered a trial to see what difference extra chemotherapy could make.
Unlike a standard trial, each sub trial will be analysed at four stages to assess the activity and effectiveness of the drug. The flexible trial design allows researchers to stop testing treatments that are not working in enough patients and replace them with other targeted drugs, including new drugs as they become available.
This approach is also flexible enough so that new biomarkers can be added as and when there is strong evidence for them – having been developed within FOCUS4 or from other trials.
Chief investigator Professor Tim Maughan, of the University of Oxford and Oxford University Hospitals NHS Trust, said: "Research has shown that no two bowel cancers are identical, yet we treat them in the same way. FOCUS4 is a completely new approach to clinical trials for cancer – rather than focusing on an individual drug we are trying to find the best treatment for each of our patients.
"The trial takes advantage of the 'rest period' that patients with advanced bowel cancer have after being treated with four months of chemotherapy – they would normally be monitored until their cancer starts growing again and then offered more chemotherapy. In FOCUS4, they will receive the new treatments until the tumour starts growing.
"We hope this approach could be a game changing moment for the treatment of bowel cancer and for how we run clinical trials to tailor treatments to each individual."
Two of the sub trials are currently open and further ones are expected to open in 2015. Patients will be enrolled onto the trial from 132 centres across the UK with overall co-ordination through the Medical Research Council (MRC) Clinical Trial Unit at UCL, where the FOCUS4 design was developed.
Another important aspect of the trial is that all the samples will be tested at two central labs, in Cardiff and Leeds, rather than at each hospital. This will mean that it will be easier to test for new biomarkers as they become available.
Dame Sally Davies, Chief Medical Officer and Chief Scientific Adviser at the Department of Health, said: "That both the NIHR, MRC and Cancer Research UK are supporting this trial illustrates the huge leap forward it could represent in understanding how we can identify the most effective anti-cancer treatment for an individual, and the potential to make a real difference to people's lives."
Professor Richard Kaplan, FOCUS4 programme lead at the MRC Clinical Trials Unit at UCL, said: "The capability of handling multiple sub-types of bowel cancer, multiple drugs and multiple biomarkers makes FOCUS4 potentially a far more efficient platform than conventional trial designs for speeding up identification of the best biomarker and drug combinations."
Kate Law, director of clinical research at Cancer Research UK, said: "The phenomenal pace of cancer research means that we are learning more about the disease every day. The flexibility of this trial will allow the researchers to respond to the latest findings and add in extra sub trials as new markers and drugs become available. This has the potential to answer many questions about bowel cancer in just one trial."
Explore further: New trial of personalised cancer treatment begins in Oxford
Medical Xpress on facebook
Related Stories
New trial of personalised cancer treatment begins in Oxford
Mar 14, 2014
(Medical Xpress)—The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.
New drug extends life in women with advanced ovarian cancer
Nov 05, 2013
Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National ...
Cancer drug RG7813 launches in its first clinical trial
Mar 28, 2014
(Medical Xpress)—A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers.
New biomarker for bowel cancer could help predict if disease will spread
Jul 24, 2013
Scientists have identified a protein that could play a crucial role in recognising whether bowel cancer patients need chemotherapy as there is a high risk of their bowel cancer spreading, according to a new study1 published ...
Re-thinking cancer treatment
Nov 18, 2013
A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.
Recommended for you
Cell metabolism discovery could lead to treatments for cancer, common cold
32 minutes ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
12 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
14 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
14 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
Experts question routine mammograms in elderly
14 hours ago
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another ...
Medication does not help prevent ED following radiation therapy for prostate cancer
14 hours ago
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue ...
User comments
© Medical Xpress 2011-2014, Science X network
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs and new biomarkers as they become available.
The first trial of its kind in solid tumours, FOCUS4 will divide around 2,400 patients into different, smaller groups depending on specific biomarkers found in their tumour. These biomarkers will then be used to predict the targeted treatments that patients are most likely to benefit from.
The trial is jointly funded by the Medical Research Council (MRC) and National Institute for Health Research (NIHR) through the Efficacy & Mechanism Evaluation (EME) programme and Cancer Research UK, through its partnership with Stand up to Cancer and Channel 4.
Patients with advanced bowel cancer will first receive the standard four months of chemotherapy and have their cancer biopsy analysed for a number of biomarkers at the same time. Based on the test results, patients will be offered enrolment into a sub trial that will test a new drug targeted at their specific type of bowel cancer.
And for those who don't have any of these biomarkers, or if there are no open sub trials for their biomarkers, they will be offered a trial to see what difference extra chemotherapy could make.
Unlike a standard trial, each sub trial will be analysed at four stages to assess the activity and effectiveness of the drug. The flexible trial design allows researchers to stop testing treatments that are not working in enough patients and replace them with other targeted drugs, including new drugs as they become available.
This approach is also flexible enough so that new biomarkers can be added as and when there is strong evidence for them – having been developed within FOCUS4 or from other trials.
Chief investigator Professor Tim Maughan, of the University of Oxford and Oxford University Hospitals NHS Trust, said: "Research has shown that no two bowel cancers are identical, yet we treat them in the same way. FOCUS4 is a completely new approach to clinical trials for cancer – rather than focusing on an individual drug we are trying to find the best treatment for each of our patients.
"The trial takes advantage of the 'rest period' that patients with advanced bowel cancer have after being treated with four months of chemotherapy – they would normally be monitored until their cancer starts growing again and then offered more chemotherapy. In FOCUS4, they will receive the new treatments until the tumour starts growing.
"We hope this approach could be a game changing moment for the treatment of bowel cancer and for how we run clinical trials to tailor treatments to each individual."
Two of the sub trials are currently open and further ones are expected to open in 2015. Patients will be enrolled onto the trial from 132 centres across the UK with overall co-ordination through the Medical Research Council (MRC) Clinical Trial Unit at UCL, where the FOCUS4 design was developed.
Another important aspect of the trial is that all the samples will be tested at two central labs, in Cardiff and Leeds, rather than at each hospital. This will mean that it will be easier to test for new biomarkers as they become available.
Dame Sally Davies, Chief Medical Officer and Chief Scientific Adviser at the Department of Health, said: "That both the NIHR, MRC and Cancer Research UK are supporting this trial illustrates the huge leap forward it could represent in understanding how we can identify the most effective anti-cancer treatment for an individual, and the potential to make a real difference to people's lives."
Professor Richard Kaplan, FOCUS4 programme lead at the MRC Clinical Trials Unit at UCL, said: "The capability of handling multiple sub-types of bowel cancer, multiple drugs and multiple biomarkers makes FOCUS4 potentially a far more efficient platform than conventional trial designs for speeding up identification of the best biomarker and drug combinations."
Kate Law, director of clinical research at Cancer Research UK, said: "The phenomenal pace of cancer research means that we are learning more about the disease every day. The flexibility of this trial will allow the researchers to respond to the latest findings and add in extra sub trials as new markers and drugs become available. This has the potential to answer many questions about bowel cancer in just one trial."
Explore further: New trial of personalised cancer treatment begins in Oxford
Medical Xpress on facebook
Related Stories
New trial of personalised cancer treatment begins in Oxford
Mar 14, 2014
(Medical Xpress)—The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.
New drug extends life in women with advanced ovarian cancer
Nov 05, 2013
Women with ovarian cancer that has returned after previous treatment had their life extended by almost three months after treatment with a drug called Cediranib, according to trial results presented today at the National ...
Cancer drug RG7813 launches in its first clinical trial
Mar 28, 2014
(Medical Xpress)—A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers.
New biomarker for bowel cancer could help predict if disease will spread
Jul 24, 2013
Scientists have identified a protein that could play a crucial role in recognising whether bowel cancer patients need chemotherapy as there is a high risk of their bowel cancer spreading, according to a new study1 published ...
Re-thinking cancer treatment
Nov 18, 2013
A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.
Recommended for you
Cell metabolism discovery could lead to treatments for cancer, common cold
32 minutes ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
The Sun's campaign may actually harm women
12 hours ago
A breast check campaign by The Sun newspaper may actually harm women, warns Glasgow general practitioner Margaret McCartney today.
Screening for liver cancer in patients with cirrhosis
14 hours ago
In a systematic review and meta-analysis of 47 studies with 15,158 patients, Amit Singal (University of Texas Southwestern Medical Center) and colleagues found that patients with cirrhosis who underwent surveillance (via ...
Likely culprit in spread of colon cancer identified
14 hours ago
New research at Washington University School of Medicine in St. Louis and Vanderbilt University Medical Center in Nashville has implicated a poorly understood protein called PLAC8 in the spread of colon cancer.
Experts question routine mammograms in elderly
14 hours ago
Doctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another ...
Medication does not help prevent ED following radiation therapy for prostate cancer
14 hours ago
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment